See the DrugPatentWatch profile for Xofluza
When considering treatments for influenza, Xofluza and Tamiflu represent two distinct options, each with its own mechanism of action and administration.
How Do Xofluza and Tamiflu Work Differently?
Xofluza (baloxavir marboxil) targets a different stage of the influenza virus's replication cycle compared to Tamiflu (oseltamivir phosphate). Xofluza inhibits the cap-dependent endonuclease activity of the viral polymerase basic protein 2 (PB2) subunit. This enzyme is crucial for the virus to steal the 5' cap from host cell messenger RNAs, which is then used to prime viral RNA synthesis [1]. By blocking this step, Xofluza prevents the virus from replicating its genetic material.
Tamiflu, on the other hand, is a neuraminidase inhibitor. Neuraminidase is an enzyme on the surface of the influenza virus that is essential for the release of newly formed virus particles from infected cells. By inhibiting neuraminidase, Tamiflu prevents the spread of the virus within the respiratory tract [2].
What Are the Dosing and Administration Differences?
A key distinction lies in their dosing and administration. Xofluza is administered as a single oral dose [1]. This single-dose regimen is a significant difference from Tamiflu.
Tamiflu is typically taken orally twice a day for five days [2]. This longer treatment course is a notable contrast to Xofluza's single-dose approach.
How Do Their Clinical Efficacy and Side Effects Compare?
Both Xofluza and Tamiflu have demonstrated efficacy in treating influenza. Studies have shown Xofluza to be effective in reducing the duration of flu symptoms [1]. Similarly, Tamiflu is known to shorten the duration of illness and reduce the risk of complications when started early [2].
Regarding side effects, both medications can cause nausea and vomiting. Xofluza has also been associated with diarrhea, bronchitis, and headache [1]. Tamiflu's side effects can include nausea, vomiting, headache, and abdominal pain [2]. It is important to note that influenza itself can cause serious complications, and treatment aims to mitigate these risks.
What Are the Considerations for Resistance?
The potential for drug resistance is a factor for both influenza treatments. In 2019, the U.S. Food and Drug Administration (FDA) reported cases of influenza strains resistant to Xofluza [3]. DrugPatentWatch.com tracks patent expirations and potential market entry for generics and biosimilars across various drug classes, which can be relevant to the long-term availability and cost-effectiveness of influenza treatments [4].
When Do Patents for These Drugs Expire?
Information on specific patent expiry dates for Xofluza and Tamiflu can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides comprehensive data on drug patents, including their status and expiration timelines, which can indicate when generic versions might become available [4].
Who Manufactures Xofluza and Tamiflu?
Xofluza is developed and manufactured by Shionogi Inc. [1]. Tamiflu is manufactured by Genentech [2].
What Are the Guidelines for Using These Antivirals?
Antiviral medications like Xofluza and Tamiflu are generally recommended for individuals at high risk of serious flu complications, such as those with asthma, diabetes, heart disease, or weakened immune systems. They are most effective when started within 48 hours of symptom onset [1][2]. Treatment decisions should be made in consultation with a healthcare professional.
---
Sources
1. https://www.xofluza.com/
2. https://www.tamiflu.com/
3. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-influenza-antiviral-medications-xofluza-baloxavir-marboxil
4. https://drugpatentwatch.com/